Abeona Therapeutics director files Form 3
Abeona Therapeutics Inc. insider data show that Keith A. Goldan is a reporting person serving as a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Abeona Therapeutics Inc. insider data show that Keith A. Goldan is a reporting person serving as a director. The Form 3 insider filing excerpt lists no buy, sell, acquisition, or disposition transactions and shows no derivative positions or holding entries in the provided data.
Key Figures
Key Terms
Form 3 regulatory
insider filing regulatory
reporting person regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Abeona Therapeutics (ABEO) Form 3 filing show for Keith A. Goldan?
Are there any stock purchases or sales reported for ABEO director Keith A. Goldan?
Does the Abeona Therapeutics Form 3 show any derivative securities for Keith A. Goldan?
What does the transaction summary indicate in the ABEO Form 3 insider data?
AI-generated analysis. How Rhea-AI works. Not financial advice.